Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.53 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.37 |
| ▸ | BCL2 | P10415 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19014652 | 0.86 | PTGS2 (0.45) | PTGS2PTGS1BCL2L1SLC6A3BCL2 | |
| SCHEMBL3420849 | 0.82 | PTGS2 (0.49) | PTGS2PTGS1BCL2L1SLC6A3BCL2 | |
| SCHEMBL1700136 | 0.80 | PTGS2 (0.48) | PTGS2PTGS1BCL2L1SLC6A3BCL2 | |
| SCHEMBL2484636 | 0.79 | PTGS2 (0.47) | PTGS2PTGS1BCL2L1SLC6A3BCL2 | |
| SCHEMBL30074975 | 0.79 | PTGS1 (0.41) | PTGS2PTGS1BCL2L1SLC6A3BCL2 | |
| SCHEMBL24775450 | 0.78 | PTGS2 (0.45) | PTGS2PTGS1BCL2L1SLC6A3BCL2 | |
| SCHEMBL22560752 | 0.78 | PTGS2 (0.45) | PTGS2PTGS1BCL2L1SLC6A3BCL2 | |
| SCHEMBL22560741 | 0.78 | PTGS2 (0.45) | PTGS2PTGS1BCL2L1SLC6A3BCL2 | |
| SCHEMBL1959392 | 0.78 | PTGS2 (0.45) | PTGS2PTGS1BCL2L1SLC6A3BCL2 | |
| SCHEMBL24896301 | 0.77 | PTGS2 (0.44) | PTGS2PTGS1BCL2L1SLC6A3BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022056737-A1 | SYNTHETIC METHOD FOR VENETOCLAX INTERMEDIATE AND ANALOGUES THEREOF | 广东莱佛士制药技术有限公司 | 2022-03-24 | — | — | WO | claimed |
| WO-2010065865-A2 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-06-10 | — | — | WO | claimed |
| EP-2970263-B1 | PROCESSES FOR THE PREPARATION OF AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2018-05-09 | — | — | EP | disclosed |
| US-9156856-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20130184278-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2013-07-18 | — | — | US | disclosed |
| EP-2613769-A1 | MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | Abbvie Inc. (US) | 2013-07-17 | — | — | EP | disclosed |
| EP-2576546-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbvie Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2012121758-A1 | MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBVIE INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| WO-2010065865-A2 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184278-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | PTGS2 172/4885PTGS1 265/4885BCL2L1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.